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Abstract
Both normal development and neoplastic progression involve cellular transitions from one
physiological state to another. Whereas much is being discovered about signal transduction
networks involved in regulating these transitions, little progress has been made in identifying
the higher order genetic determinants that establish and maintain mammary cell identity and
dictate cell type-specific responses to mammotropic signals. Homeobox genes are a large
superfamily of genes whose members function in establishing and maintaining cell fate and
cell identity throughout embryonic development. Recent genetic and expression analyses
strongly suggest that homeobox genes may perform similar functions at specific
developmental transition points in the mammary gland. These analyses also suggest that
homeobox genes may play a contributory or causal role in breast cancer.
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Introduction
The mammary gland is a remarkable organ with respect to
its development and functional differentiation. It is also
remarkable with respect to the consequences on mam-
malian life should development become abnormal, leading
either to lactational failure or, most importantly, mammary
cancer.
Unlike most mammalian organs, which develop primarily
embryonically with a more or less linear progression toward
functional maturity, development of the mammary gland is
primarily postpubertal and may be divided into both a linear
and a cyclical phase (Fig. 1) (see [1–3] for detailed reviews).
These phases can be characterized further as a series of
highly orchestrated transitions, or switches, in which critical
developmental decisions are made concerning cell differ-
entiation, pattern formation and cell function. While muta-
tions have been identified that block or delay most of these
transitions (primarily in signal transduction networks), the
higher order genetic determinants of cell identity that
dictate cell type specific responses are largely unknown.
Among other candidates, one superfamily of genes pre-
sents itself as capable of regulating developmental deci-
sions during these transitions: the homeobox genes. As a
general principle, homeobox genes encode transcription
factors that play key roles in the determination and mainte-
nance of cell fate and cell identity [4–7]. Homeobox genes
share a common nucleotide sequence motif (the homeo-
box) encoding the roughly 61 amino acid homeodomain.
The homeodomain, in turn, is a helix-turn-helix DNA-
binding domain of the functional transcription factor. Evo-
lutionary relationships and family classifications are
determined based upon the degree of identity and
similarity among homeodomains followed by comparative
analyses of amino acid sequences both amino-terminal
and carboxyl-terminal to the homeodomain [8–10]. These
terminal sequences vary considerably from protein tohttp://breast-cancer-research.com/content/2/3/158
protein and, indeed, may demonstrate no evidence of evo-
lutionary or functional relationship whatsoever.
Homeobox genes are found in animals ranging from hydra
to humans (as well as fungi and plants). Over evolutionary
time, the number of homeobox genes has increased and
their functions have been reengineered to meet the
demands of increasingly diverse developmental processes.
To date, there are well over 100 homeobox genes identi-
fied in the human, with a comparable number of homologs
identified in the mouse [10].
In mammals, homeobox genes reign over the specification
of the overall body plan and are known to play key roles in
a variety of developmental processes including central
nervous system and skeletal development, limb and digit
specification, and organogenesis. Mutations in homeobox
genes can cause dramatic developmental defects includ-
ing loss of specific structures as well as ‘homeotic trans-
formations’, in which one body part or segment is
converted to the likeness (identity) of another. Some
homeobox genes appear to serve cell autonomous func-
tions in differentiation and cell cycle control; others serve
noncell autonomous functions such as pattern formation
and mediation of reciprocal tissue interactions.
At least five difficulties present themselves when trying to
understand the functions of individual members of such a
large superfamily of genes. First and foremost, exceptionally
little is known about the number and identity of target genes
controlled directly or indirectly by any mammalian homeobox
gene, although it appears that much of the Drosophila
genome is under homeobox gene control [11]. Second,
only slightly more is known about upstream genes that
control homeobox gene expression and function. Recent
efforts in both Drosophila and mice demonstrate that estab-
lishment and maintenance of restricted homeobox gene
expression is controlled, in part, by combinatorial activity of
trithorax and polycomb group genes (which themselves are
highly regulated) [12–15]. Third, homeobox genes do not
generally act alone to determine cell identity. Rather, in
many cases, it appears to be the combinatorial spatially and
temporally regulated pattern of homeobox genes function-
ing in a given cell (a ‘homeobox code’) that determines the
cell’s identity [6,16,17]. In fact, in some cases, important
functions of a given homeobox gene can be masked by
compensatory function of a related homeobox gene. Fourth,
to further complicate the issue, some homeodomain pro-
teins are known to interact physically with other home-
odomain proteins (eg PBX and MEIS or PBX and HOX) or
other cofactors to control downstream target gene speci-
ficity [18–20]. Finally, many homeobox gene mutations are
(or will be) embryonic or perinatal lethal, making analysis of
the development of adult organs particularly challenging.
This current state of affairs makes it difficult to develop
mechanistic models for the function of a given homeobox
gene, especially in the mammary gland where none of these
issues have been investigated adequately.
In addition to roles in normal development, altered homeo-
box gene function is implicated in the development of
cancers, particularly leukemias and rhabdomyosarcomas,
as well as those of the breast, prostate, kidney, colon, skin
and brain. With the exception of a role in breast cancer,
this subject has been reviewed extensively [21–24].
Homeobox genes clearly occupy a prominent position in the
developmental regulatory heirarchy, yet homeobox genes
have received little attention with respect to mammary gland
organogenesis, functional differentiation and cancer. It is the
purpose of this review to highlight a few known and sus-
pected roles of homeobox genes in controlling developmen-
tal decisions and neoplasia in the mammary gland, and to
point out some gaping holes in our understanding that study
of homeobox genes may help to fill.
Transitions and switches in mammary gland
development
The linear phase
Differentiation of the embryonic mammary gland
The mammary epithelium is an ectodermal derivative. As
such, among the first distinctions that must be made is the
differentiation of presumptive mammary epithelium from
tissue that would otherwise form skin, hair follicles or other
Figure 1
Phases of mammary gland development. Proliferative development in
virgin animals is represented by the linear portion of the diagram.
Cyclical development is represented by the circular portion of the
diagram.Breast Cancer Research    Vol 2 No 3 Lewis
ectodermally derived structures. This differentiation occurs
in at least two major stages. The first stage begins about
day 10 of gestation (E10) with the establishment of the
mammary streaks, two lines of epidermally derived thick-
ened epithelium that run anterior®posterior, symmetrically
displaced off the ventral midline. These streaks represent
the first morphological evidence of mammary pattern for-
mation and differentiation.
The second stage occurs around E11 with the definition of
the nipple region. Presumptive mammary epithelium forms a
lens-shaped disk that becomes associated with underlying
condensed mammary mesenchyme. The mammary epithe-
lium continues to grow to form a bulb-shaped mammary
bud that elongates and invades the condensed mes-
enchyme. Mammary epithelial cell identity is firmly estab-
lished as early as E12.5 (the bud stage), as evidenced by
the ability to transplant the presumptive mammary gland into
a cleared fat pad and regenerate a ductal tree (CW Daniel,
G Robinson, personal communication).
Invasion of the mammary fat pad precursor mesenchyme
As the mammary bud elongates into a mammary sprout, it
reaches a second mesenchyme, the fat pad precursor
mesenchyme, and undergoes a small amount of branching
morphogenesis to form the rudimentary gland of the
neonate. Several genes are known to act either at or
before this critical transition to allow further growth or to
control establishment of sexual dimorphism of the mouse
mammary gland (eg Lef1, PThRP, PPR1) [25–27]. Tissue
recombination experiments demonstrate that mammary
mesenchyme and fat pad mesenchyme affect the growth
of mammary epithelium in dramatically different ways, sug-
gesting fundamental differences in their identities and bio-
logical properties with respect to tissue interactions (see
[2]). How these differences are established is unknown.
Growth initiation, cellular differentiation and growth arrest
From birth to puberty, the gland remains rudimentary and rel-
atively growth quiescent. At puberty, ovarian hormones stim-
ulate rapid and invasive ductal elongation driven by growth of
a structure called the terminal end bud, which consists of
four to six layers of relatively undifferentiated ‘body cells’ and
a surrounding single layer of ‘cap cells’. These two popula-
tions differentiate into lumenal epithelial cells (also consisting
of multiple cell types) and myoepithelial cells, respectively, as
the subtending duct is formed [1,28]. Whereas a variety of
individual cell types are known to exist and their developmen-
tal capacities have begun to be explored, virtually nothing is
known about how these cell lineages and fates are estab-
lished in the first place.
Upon reaching the limits of the fat pad at ductal maturity,
ductal elongation ceases and terminal end buds regress
to leave a branched system of differentiated ducts. These
ducts will remain relatively quiescent as long as the animal
remains virgin. How this growth control is achieved and
maintained is not known, although it probably involves
members of the transforming growth factor-b superfamily.
The cyclical phase: lobuloalveolar differentiation, lactation,
involution and gland remodeling
Hormonal changes during pregnancy initiate a cyclical
phase of development in which there is a dramatic transi-
tion from a predominantly ductal to a predominantly
lobuloalveolar gland morphology. Lobuloalveolar progeni-
tor cells located within the ducts proliferate to form alveo-
lar buds, which further differentiate to form the alveoli.
Near midpregnancy, the alveolar epithelium acquires the
capacity to produce milk proteins (the stage I transition of
lactogenesis) but secretory function is inhibited. At parturi-
tion, inhibition of secretory function is released and these
cells begin to secrete large quantities of milk (the stage II
transition of lactogenesis). Upon weaning, milk secretion
ceases and the gland involutes. During involution, most
alveolar cells undergo apoptosis (programed cell death),
while a residual epithelial population remodels itself back
into a ductal tree to await the next pregnancy.
Of course, there are known hormonal and growth factor
signals that control some of these transitions, but little is
known about how epithelial and stromal cells are poised to
respond to such signals or how the resultant differentiated
state is maintained.
Homeobox genes in embryonic and postnatal
mammary gland development
Judging from their properties in the development of other
organs, it is likely that homeobox genes may function at
many of the transition points already described. The
approach that has been most useful thus far in investigat-
ing mammary homeobox gene function is to determine
which homeobox genes are expressed in the gland, char-
acterize when and where they are expressed throughout
development, and assay their function in vitro or, prefer-
ably, in vivo (Table 1). Unfortunately, many of the current
studies are in their early stages and have been limited to a
single detection technique (eg reverse transcription poly-
merase chain reaction) or to a particular developmental
stage with no further analysis. Selected analyses, conve-
niently divided by gene family, are now highlighted with
historical context whenever possible.
Hox/HOX
In the mouse (and human), 39 known Hox (HOX) complex
genes are arranged in four paralogous gene clusters, one
on each of four different chromosomes. These genes are
primarily responsible for anterior–posterior patterning of the
body and limbs but organ-specific functions are also known.
Targeted disruption (knockout) strains exist for most Hox
genes, as do a limited number of overexpressing transgenic
strains. Both types of mutants have rarely been examined forhttp://breast-cancer-research.com/content/2/3/158
mammary defects and tumors, and overall phenotypic analy-
sis of single gene mutations has been somewhat hampered
by functional compensation from paralogous genes within
the complex itself. Nevertheless, it is already clear that some
Hox genes are critically important for proper mammary
gland development and function (Table 1).
Early immunohistochemical studies and screens based on
polymerase chain reaction first detected homeobox gene
expression in mammary epithelial cell lines and tumors
[29,30]. Subsequently, Friedmann and coworkers identi-
fied several Hox genes that were expressed in the normal
mouse mammary gland and associated neoplasias
(Table 1) [31•,32]. In situ hybridization demonstrated that
many of these genes are expressed either in the mammary
epithelium or in the periductal stroma, or both (Fig. 2).
Several genes, including Hoxc-6, Hoxc-8, Hoxd-8,
Hoxd-9 and  Hoxd-10, appeared to be regulated develop-
mentally. Most intriguing was the demonstration that
expression of some homeobox genes was sensitive to
manipulation of the estrogen level. Together, these data
provided the first substantive clues that homeobox genes
are important for normal mammary development.
Soon after, Srebrow et al [33•] identified five Hox genes
expressed in CID-9 mouse mammary epithelial cells.
When these cells are cultured on reconstituted basement
membrane in the presence of lactogenic hormones, they
form alveolar-like hollow spheres and differentiate to
express milk proteins. Expression of two genes, Hoxa-1
and Hoxb-7, was shown to be downregulated by exoge-
nous basement membrane, suggesting that homeobox
gene expression may be modulated in vivo by interactions
between epithelial cells and components of the basement
membrane. Such interactions have been shown to be criti-
cal for mammary differentiation and function, and tend to
be altered on neoplastic progression [34–37].
Taking cue from these studies, Chen and Cappechi [38•]
demonstrated compromised mammary function in mutant
mice carrying various deletions of paralogous genes
Hoxa-9, Hoxb-9 and Hoxd-9. Single mutant lines disrupted
for either Hoxa-9 or Hoxb-9 (heterozygous at the remaining
relevant  Hox loci) showed only a small decrease in
newborn survival, while the Hoxd-9 disruption alone
reduced survival to below 50%. Double mutant combina-
tions showed synergistic interactions that reduced
newborn survival well below the additive expected values
for each single mutation, suggesting functional cooperativ-
ity. Dams with the most severely affected genotypes
(Aabbdd,  aaBbdd and  aabbdd) demonstrated marked
hypoplasia of the mammary gland after parturition with
gland morphology resembling that of a midpregnant animal.
During embryogenesis, Hoxb-9 and Hoxd-9 are each
expressed in condensed mammary mesenchyme sur-
rounding the epithelial bulb, suggesting roles in mes-
enchyme condensation or in modulation of epithelial–mes-
enchymal interactions during early mammary gland
development [38•]. Unfortunately, in situ hybridization
against  Hoxa-9 and  Hoxb-9 using adult tissues has not
been performed. However, Friedmann has examined
expression of Hoxd-9 throughout postnatal development
and showed it to be expressed highly in periductal fibro-
blasts and ductal epithelium in the virgin, but only
expressed weakly in these cell types during pregnancy.
Interestingly,  Hoxd-9 showed enhanced expression in
developing alveolar epithelium relative to subtending
ducts, consistent with its apparent role in alveolar differen-
tiation during pregnancy.
In situ hybridization has also demonstrated expression of
Hoxd-10 in both epithelium and stroma with elevated levels
in the epithelium of developing and secreting alveoli. These
observations suggested a role in lobuloalveolar differentia-
tion or the transition from pregnancy to lactation. Consistent
with this hypothesis, targeted disruption of Hoxd-10 led to
lactation failure in a significant percentage of homozygous
mutant animals ([39]; Lewis MT, Daniel CW, unpublished
results). In glands of affected animals, alveolar development
progressed through late pregnancy but failed, in whole or in
part, to make the transition to lactation. In severely affected
animals, alveoli failed to expand and increased pup mortality
was observed. Together with the data for the group 9 par-
alogs, these observations firmly establish a functional role
for Hox genes in alveolar differentiation and function.
Msx
Msx is a small family of three related genes. In the mouse,
at least two members (Msx-1 and Msx-2) appear to play
roles in mediating inductive tissue interactions during
organogenesis. Only Msx-1 and Msx-2 have been exam-
ined in the mouse mammary gland [40•,41•].
Expression of Msx-1 and Msx-2 has been demonstrated in
mammary buds during embryogenesis, with both genes
expressed in the epithelium [41•]. In contrast, in postnatal
mice, Msx-1 and Msx-2 are expressed in reciprocal tissue
compartments, with Msx-1 expressed in the epithelium
and  Msx-2 expressed in the periductal stroma (Fig. 2). The
expression of Msx-2 in the fat pad was dependent on the
presence of mammary epithelium. Results are suggestive
of a fundamental transition in epithelial–stromal signaling
that leads to tissue compartment switching of Msx-2
expression during organogenesis.
Expression studies also suggested a potential role in media-
tion of hormone responses. The Msx-2 mRNA was down-
regulated in glands of ovariectomized and antiestrogen
treated animals, and upregulated by estrogen replacement
in ovariectomized animals. So far, Msx-1, Msx-2 and
Msx-1/Msx-2 targeted disruption strains have been exam-B
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Table 1
Summary of homeobox gene expression and function in mammary gland development and neoplasia
Gene Gene Expression Expression altered in
family namea detected inb: Methodc neoplasias? Possible regulation? Mammary or in vitro phenotype? Reference
Hox/HOX Hoxa-1 MG (UD) RT-PCR; Northern OE (freq.) Extracellular matrix  [31•,33•]
Scp2, CID-9 components
HOXA-1 MCF7 RT-PCR Retinoic acid [63,30]
Hoxa-5 CID-9 RT-PCR [33•]
Hoxa-7 MG RT-PCR [31•]
HOXA-7 MG RT-PCR 1
Hoxa-9 MG RT-PCR KO: lactational defects [38•]
HOXA-10 MCF7 RT-PCR Vitamin D OE in MCF7: promotes cell cycle  [30,64]
arrest at G1
Hoxb-6 MG RT-PCR; Northern Lost [31•]
HOXB-6 MCF7 RT-PCR [30]
Hoxb-7 MG (E+S) Northern; in situ UE Extracellular matrix OE in SkBr3 cells: bFGF induction; [33•,57]
components; developmental increased proliferation; decreased
growth factor dependency
Hoxb-8 CID-9 RT-PCR [33•]
Hoxb-9 CID-9 E12.5 RT-PCR; in situ KO: lactational defects [33•,38]
Embryo (MM)
Hoxc-6 MG Northern Lost Estrogen (–); developmental [31•]
HOXC-6 MCF7; MCF7D; cDNA screen;  Variable [57,65]
Hs578Bst; RT-PCR
MCF10F; T47D
Hoxc-8 MG Northern Lost Estrogen (–); developmental [32]
HOXC-10 MG PCR of cDNA library 2
Hoxd-3 MG (UD) Northern OE (rarely) [32]
Hoxd-4 MG (E) In situ Lost [32]
Hoxd-8 MG Northern Lost Developmental [32]
Hoxd-9 MG (E+S); RT-PCR;  Lost Developmental KO: lactational defects [32,38•]
E12.5 Embryo Northern; in situ
(MM)
Hoxd-10 MG (E+S) Northern; in situ Lost Developmental KO: lactational defects [32,39]; 2
Hoxd-11 MG (UD) Northern No [32]
Hoxd-12 MG RT-PCR; OE (myc tumor) [31•]
Northern (UD)
Msx Msx-1 E13.5 Embryo (E); Northern; in situ Maintained but variable Developmental KO: none detected in embryos [40•,41•]
MG (E)
Msx-2 E13.5 Embryo (E);  Northern; in situ Lost Estrogen; developmental KO: MG fail to form [40•]; 3
MG (S)
Iroquois related IRX-1 MG RT-PCR [48•]
IRX-2 MG; primary RT-PCR; Northern;  Maintained. expression  Developmental [48•]
tumors in situ levels or splice form
usage may be altered
in some tumorsh
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Table 1 continued
Gene Gene Expression Expression altered in
family namea detected inb: Methodc neoplasias? Possible regulation? Mammary or in vitro phenotype? Reference
IRX-3 MG RT-PCR [48•]
IRX-4 MG RT-PCR [48•]
IRX-5 MG RT-PCR [48•]
Paired domain Alx-4 MG (S) In situ Expression associated with  KO: none detected [45]
actively condensing periductal
stroma
HSIX HSIX-1 MCF7 OE Expressed in S phase OE in MCF7 abolishes X-ray induced  [58•]
of cell cycle cell cycle arrest in G2 phase
POU domain OCT-1 MCF7;MCF10; RT-PCR;  [54]
SkBr3; MDA- Western EMSA
MB453
Oct-1 MG (lact.) RT-PCR [53]
OCT-2 MCF7; MCF10; 
SkBr3 RT-PCR;  [54]
Western EMSA
OCT-3 MG (UD); MCF7;  RT-PCR OE (freq.) Form with a 5 amino acid deletion  [54]
MCF10; SkBr3;  detected in MCF7 cells
primary tumors
Oct-3 MG (lact.) RT-PCR [53]
OCT-11 MG (UD) MCF7;  RT-PCR; EMSA OE (freq.) [54]
SkBr3; MDA-
MB453; primary 
tumors
Pit-rs1 MG (lact.) RT-PCR [53]
Pou4f1 = Brn-3 MG (lact.) RT-PCR [53]
Pou4f-rs1 =  MG (lact.) RT-PCR [53]
Brn-3R
Pou3f4 = Brn-4 MG (lact.) RT-PCR [53]
Pou3f-rs1 =  MG (lact.) RT-PCR [53]
POU-IIIA
Engrailed relatedEn-1 MG Northern UE (freq.) Developmental [32]
En-2 MG (UD) Northern UD KO: none detected [32]
MOX MOX1 MG [52]
MEIS MEIS2a MG RT-PCR of cDNA library 4
MEIS2d MG RT-PCR of cDNA library  4
MRG1a MG RT-PCR of cDNA library  4
bFGF, basic fibroblast growth factor; E, epithelium; EMSA, electrophoretic mobility shift assay; freq., frequently; KO, knockout mutation; lact., lactating; M, mammary mesenchyme; MG,
mammary gland; Northern, Northern blot assay; OE, overexpressed; RT-PCR, reverse transcriptase polymerase chain reaction; S, periductal stroma; UD, undetectable; UE, underexpressed.
aHuman genes are uppercase; mouse genes are lowercase. bCell lines are listed by their common designation. If expression was detected in the intact mammary gland, the tissue compartment
is shown. cNot all detection techniques have been used on all tissue types/cell lines shown. 1Friedmann Y, Daniel CW, unpublished results; 2Lewis MT, Daniel CW, unpublished results;
3Maas R, unpublished results, cited in [41•]; 4Lewis MT, unpublished results.ined for mammary defects only during embryogenesis. No
defects in embryonic mammary gland development were
observed in Msx-1 mutants but Msx-2 and Msx-1/Msx-2
animals reportedly showed developmental defects as early
as E13.5 ([41•]; Maas R, unpublished results cited in [41•]).
As with other organs, data from the mammary gland are
consistent with a role in mediation of tissue interactions.
Because homozygous Msx-1 and Msx-2 mutations are
embryonic lethal, analyses of Msx gene function in the adult
mammary gland are largely absent. Transplantation rescue
experiments and gland reconstitution assays using embry-
onic tissue should be extremely useful in further examining
Msx gene function in the adult mammary gland [42–44].
Paired domain class
Aristaless-like
The Aristaless-like gene Alx-4 is expressed in mesenchy-
mal condensations of tissues whose development is
dependent on epithelial–mesenchymal interactions [45].
In the mammary gland, Alx-4 expression was associated
primarily with actively condensing stroma at the neck of
terminal end buds (Fig. 2). Alx4 mutants failed to comple-
ment Strong’s luxoid (lst) mutants and the two strains
show similar defects [46,47]. Interestingly, mammary
glands of lst mice appear normal, as do other ventral (but
not dorsal) structures in which Alx-4 is expressed
[45–47], although it is not clear to what extent the
mammary glands from these animals were analyzed.
Iroquois-related
At least five members of the Iroquois-related homeobox
(IRX) gene family are expressed in the human mammary
gland [48•]. One member, IRX-2, was shown to be
expressed in discrete epithelial cell lineages being found
in lumenal epithelium of both ducts and alveoli, but not
myoepithelium. IRX-2 also showed developmental regula-
tion: expression was enhanced in terminal buds and
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Figure 2
Tissue distribution of homeobox gene expression through mouse mammary gland development. Selected stages of mammary gland development
are depicted with reference to the expression patterns of several homeobox genes as demonstrated by in situ hybridization. Expression at a given
stage is shown by a bar above the stage. Bars are pattern coded to represent a unique tissue compartment or epithelial structure. Transition points
affected by a given homeobox gene mutation are denoted by a hatched box above the arrow representing the transition.terminal lobules of the immature gland but uniformly dis-
tributed in mature glands. During lactation, some alveolar
epithelial cells (~18%) showed reduced levels of mRNA
relative to adjacent strongly expressing cells. Uniform
epithelial expression was reestablished upon involution.
Mutational analyses of these genes are underway in
several laboratories.
Engrailed-related
Both Engrailed-related (En) En-1 and En-2 have been
examined in the mouse mammary gland by Northern
hybridization [32]. En-2 was not detected in any tissue
examined; in contrast, En-1 was expressed at virtually con-
stant levels through early pregnancy but was not
detectable during late pregnancy or lactation. Homozy-
gous  En-1 mutations are embryonic lethal. Because
neither embryonic glands nor epithelial transplants have
been examined, it remains possible that En-1 serves a
function in the mammary gland near the early®late preg-
nancy transition [49–51].
Other homeobox genes
Several other homeobox genes have been identified either
in intact mammary glands or from cDNA library screens.
These include members of the POU domain containing,
MOX, and MEIS gene families ([52–54]; Lewis MT, Daniel
CW, unpublished results). No functional or detailed
expression data are yet available. Given the known impor-
tance of the POU and MEIS gene families in development
and cancer, these should be among the first to be evalu-
ated for mammary function.
Intrinsic versus extrinsic function: the
Forkhead transcription factor Fkh-5/Mf3
Forkhead-related genes encode transcription factors con-
taining a divergent ‘winged helix’ homeodomain. One of
these genes, Fkh-5/Mf3, was shown to be required for
brain development and postnatal growth with most
homozygous null animals dead at birth. Surviving adult
homozygous females were unable to feed their pups, yet
did not show overt defects in mammary gland morphology
or secretory function. Further analysis showed a defect in
the milk letdown response. This defect was alleviated by
injection with oxytocin and was probably caused by
improper hypothalamic development [55,56].
This example illustrates the important point that the
mammary gland cannot be considered an isolated organ.
Rather, it must be considered an organ profoundly influ-
enced by, and dependent upon, proper neuroendocrine
function. Given that many homeobox genes affect develop-
ment of the central nervous system and endocrine organs,
it becomes imperative to demonstrate experimentally (eg
via transplantation) that observed mammary defects are
intrinsic to the gland and are not a downstream conse-
quence of an extrinsic physiologic dysfunction.
Homeobox genes in mammary neoplasia
Embryogenesis and oncogenesis share several common
features. Among them, both processes require cell prolif-
eration, modulation of cell death (apoptosis), cell motility,
invasion of surrounding tissue and neovascularization. In
embryogenesis, the cells that accomplish these tasks are
generally relatively undifferentiated. Similarly, in cancer
progression, cells that contribute to neoplasias tend to
appear relatively undifferentiated, or dedifferentiated, as
the case may be.
This consideration leads to the following hypotheses. If
cells require accurate spatial and temporal regulation of
homeobox gene expression during embryogenesis to
acquire the proper differentiated state (identity), mis-
expression of homeobox genes could lead to failure of dif-
ferentiation, loss of the differentiated state or adoption of
an alternative cell identity (a homeotic transformation). The
expression profile of homeobox genes (and their targets)
may then be taken as a crude measure of the identity or
functional state of a given cell. If so, misregulation of
homeobox genes during neoplastic progression may be
indicative of progressive alteration of epithelial cell identity.
If such cells consequently possessed inappropriate char-
acteristics (eg loss of cell cycle control, decreased apop-
tosis, altered cell–cell adhesions, altered hormone and
growth factor responses or increased protease expres-
sion, to name a few), misexpression of homeobox genes
could easily contribute to cancer initiation or progression.
While evidence has accumulated that altered homeobox
gene function plays a causal role in development of other
types of cancers, particularly leukemias, there is only cir-
cumstantial evidence for their involvement in mammary
neoplasia. However, when taken in aggregate and in the
context of cancer in other organs, a number of observa-
tions suggest a contributory role of homeobox genes in
the initiation or progression of mammary cancer. Again,
the more suggestive existing data can be easily recounted
by gene family and are now summarized.
Hox/HOX
Expression of all eight normally expressed homeobox
genes examined (Hoxb-6, Hoxb-7, Hoxc-6, Hoxc-8,
Hoxd-4, Hoxd-8, Hoxd-9 and Hoxd-10) was lost on neo-
plastic progression in a selected population of mouse
hyperplasias and tumors [32]. Conversely, three genes not
normally expressed were activated in subsets of tumors
(Hoxa-1, Hoxd-3 and Hoxd-12).
Thus far, it appears that loss of function mutations simply
affect developmental progression but that gain of function
mutations impact neoplastic progression in unpredicatable
ways. For example, loss of function mutations of
Hoxa-9/Hoxb-9/Hoxd-9 or of Hoxd-10 resulted in devel-
opmental failure, rather than tumor formation. As for gain
http://breast-cancer-research.com/content/2/3/158of function mutations, whereas overexpression of human
HOXA-10 in MCF7 cells promoted cell cycle arrest in G1,
overexpression of murine Hoxb-7 in SkBr3 mammary
cancer cells caused increased proliferation and decreased
growth factor dependency [57]. These observations
suggest that the consequences of a given Hox gene muta-
tion cannot be predicted a priori, but will depend entirely
on the nature of the mutation and on the battery of down-
stream genes misregulated as a result.
HSIX1
HSIX1 is expressed toward the end of S phase of the cell
cycle in MCF7 cells [22,58•]. Overexpression of HSIX1 in
these cells abolished the G2 cell cycle checkpoint in
response to irradiation, leading to inappropriate entry into
mitosis. Interestingly, very low expression of HSIX1 was
observed in the normal mammary gland, but elevated
expression was observed in 44% of primary breast cancers
and in an astonishing 90% of metastatic lesions. These
data represent the only known involvement of homeobox
genes in mammary cell cycle control at the G2 checkpoint.
Given that loss of this and other checkpoints is associated
with mammary cancer [59–62], these data represent the
strongest indication to date that homeobox genes may
contribute to neoplastic progression in the mammary gland.
Teasers
Msx
Msx-1 expression was maintained in all tumors examined
[40•]. In contrast, Msx-2 became undetectable in neoplasias.
Given its reportedly critical role in embryonic mammary
gland development, loss or alteration of stromal Msx-2
function in the adult mammary gland might be expected to
have profound effects on interactions between the neo-
plastic epithelium and its associated stroma.
IRX
Similar to the expression pattern observed for Msx-1,
IRX-2 expression was also maintained in all tumor types
examined [48•]. However, in some tumors, there was evi-
dence of either increased expression or altered ratios of
the two known transcripts. Since the IRX-2b transcript
lacks the homeobox found in the IRX-2a transcript, target
gene regulation may be expected to be altered.
POU domain
At least four POU class homeobox genes have been
shown to be expressed in various human breast cancer cell
lines, including OCT1, OCT2, OCT3 and OCT11 [54].
OCT3 and OCT11 were not detected in the normal human
breast samples examined. Since OCT3 is generally consid-
ered to be an embryonic transcription factor, it is conceiv-
able that these tumor cells adopted a more embryonic cell
identity. Interestingly, Oct3 has also been detected in the
normal mouse mammary gland during lactation [53], but
the significance of this observation is not known.
Conclusion
Important questions remain with respect to homeobox
gene function in the normal and neoplastic mammary
gland. The studies summarized in this review represent
only a small fraction of the homeobox genes likely to be
involved. What has become evident from the more exten-
sive studies is that, whereas a given homeobox gene
may be expressed in regulated patterns throughout
development (eg Msx-2, Hoxd-9, Hoxd-10), mutation of
that gene may overtly affect only a single transition point
or developmental stage (Fig. 2). If this general observa-
tion holds for other homeobox genes, functional analysis
will require in vivo phenotypic evaluation of mutant
animals throughout mammary organogenesis, including
embryogenesis.
Despite the temptation to try, a unified model for homeobox
gene function in the mammary gland is unlikely to be devel-
oped given the diverse functions and complex interactions
known for many of these genes. As a consequence, the
mechanistic details of how the various homeobox genes
dictate mammary gland identity, form and function will
require years of effort and careful attention to information
derived from other model systems, particularly Drosophila.
However, a general framework can be postulated based on
data gathered thus far and by analogy with known roles in
other organs. In all likelihood, homeobox genes control
mammary gland development and function by sequential
activation or inactivation of specific sets of homeobox
genes at specific developmental transition points. For
example,  Hoxa9,  Hoxb9 and  Hoxd9 appear to be important
for alveolar development near midpregnancy, while
Hoxd10 appears to be required at the next major transition
point, the onset of lactation. As already suggested by cur-
rently available expression data, layered on top of this tem-
poral regulation will no doubt be tissue specific and cell
type specific regulation of gene function (Fig. 2).
With respect to normal development, it is interesting to
recount what homeobox gene mutations have not been
reported to cause in the mammary gland (yet?). So far, no
alterations in nipple placement (patterning and cell iden-
tity), no alterations in mammary gland number (patterning
and cell identity), no homeotic transformation of mammary
tissues to other ectodermally derived tissues (eg those of
the sweat or sebaceous glands, skin or hair follicle) and no
demonstrated function during postnatal virgin develop-
ment or early pregnancy have been observed.
As for a possible role in the development of mammary
cancer, the initial case is far weaker than one might hope.
However, lack of solid evidence at this early stage should
not be taken as an indication that the hypothesis is funda-
mentally flawed. There are still a huge number of targeted
disruption strains as well as appropriately engineered
strains that overexpress candidate oncogenic homeobox
Breast Cancer Research    Vol 2 No 3 Lewisgenes to be made and examined. For example, notably
absent from current studies, or poorly understood, are
those gene families that have been implicated causally in
development of other types of cancer, including PBX, PAX
and MEIS.
Homeobox genes clearly represent attractive candidates
for the control of mammary development and neoplastic
progression. Unfortunately, given the limitations recounted
in the introduction of this review, analysis of homeobox
gene expression and function in mammary gland develop-
ment and neoplasia will be an exceptional undertaking. For-
tunately, the mammary gland has several advantages over
many other developmental models that bypass many of
these potential problems. Identification of target genes,
upstream regulators and cofactors will be enhanced signifi-
cantly by the coupling of mouse developmental genetics
with powerful gene expression analysis techniques such as
DNA microarray and real-time reverse transcription poly-
merase chain reaction, for which the mammary gland pro-
vides ample material. The problem of embryonic or
perinatal lethality, particularly with animals carrying combi-
natorial mutations, can be addressed using two powerful
approaches. First, engineered mouse strains carrying
tissue-restricted gene disruptions or overexpressing trans-
genes can be generated, which should allow genetic analy-
ses of otherwise lethal or detrimental mutant combinations.
Second, transplantation techniques have been developed
that allow transplantation of mammary epithelium or intact
mammary glands from embryonic and postnatal sources
into wild type host animals. Such manipulations allow
development of otherwise moribund mammary tissue in a
physiologically relevant in vivo setting.
The study of homeobox gene function in the mammary
gland is truly a daunting task but, given what we already
know, it should be well worth the effort.
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